CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy

被引：0
|
作者：
Heilbrun, L. K.
Khanna, A.
Venkatramanamoorthy, R.
Shields, A. F.
Philip, P. A.
Zalupski, M. M.
El-Rayes, B. F.
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Wayne State Univ, Detroit, MI USA
[3] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15094
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Pretreatment level of CA 19-9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy
    Gansl, R. C.
    Reis, P. T.
    Tabacof, J.
    Simon, S. D.
    Machado, M. C.
    Borghesi, G.
    Saad, E. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] CA 19-9 Response A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma
    Diaz, Celso L.
    Cinar, Pelin
    Hwang, Jimmy
    Ko, Andrew H.
    Tempero, Margaret A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (12): : 898 - 902
  • [23] The impact of CA 19-9 on survival in patients with clinical stage I pancreatic cancer
    Melucci, Alexa D.
    Chacon, Alexander C.
    Burchard, Paul R.
    Ullman, Nicholas A.
    Tsagkalidis, Vasleios
    Casabianca, Anthony S.
    Reitz, Alexandra
    Swift, David A.
    Goyal, Subir
    Switchenko, Jeffrey M.
    Carpizo, Darren R.
    Shah, Mihir Maheshkumar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Impact of CA 19-9 on Survival in Patients with Clinical Stage I Pancreatic Cancer
    Melucci, Alexa D.
    Chacon, Alexander C.
    Burchard, Paul R.
    Ullman, Nicholas A.
    Tsagkalidis, Vasleios
    Casabianca, Anthony S.
    Reitz, Alexandra C.
    Swift, David A.
    Goyal, Subir
    Switchenko, Jeffrey
    Carpizo, Darren R.
    Shah, Mihir M.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 445 - 446
  • [25] Evaluation of CA 19-9, a predictive biomarker of response and survival in patients undergoing chemotherapy for metastatic pancreatic ductal adenocarcinoma
    Doraid, Alrifai
    Styliani, Germanou
    Debashis, Sarker
    Ross, Paul J.
    Anna-Mary, Young
    Jason, Chow
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] CA 19-9 as a predictor of cancer in the presence of pancreatic stricture demonstrated by ERCP
    Kirk, K
    Kasmin, FE
    Cohen, SA
    Siegel, JH
    GASTROENTEROLOGY, 2001, 120 (05) : A609 - A609
  • [27] Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
    Katz, Matthew H. G.
    Varadhachary, Gauri R.
    Fleming, Jason B.
    Wolff, Robert A.
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Vauthey, Jean-Nicolas
    Abdalla, Eddie K.
    Sun, Charlotte C.
    Wang, Huamin
    Crane, Christopher H.
    Lee, Jeffrey H.
    Tamm, Eric P.
    Abbruzzese, James L.
    Evans, Douglas B.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) : 1794 - 1801
  • [28] Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
    Matthew H. G. Katz
    Gauri R. Varadhachary
    Jason B. Fleming
    Robert A. Wolff
    Jeffrey E. Lee
    Peter W. T. Pisters
    Jean-Nicolas Vauthey
    Eddie K. Abdalla
    Charlotte C. Sun
    Huamin Wang
    Christopher H. Crane
    Jeffrey H. Lee
    Eric P. Tamm
    James L. Abbruzzese
    Douglas B. Evans
    Annals of Surgical Oncology, 2010, 17 : 1794 - 1801
  • [29] CA 19-9 as a predictor of TNM stage for pancreatic adenocarcinoma
    Kowalski, T
    Loren, D
    Raza, A
    Setty, S
    Rosato, E
    GASTROENTEROLOGY, 2004, 126 (04) : A30 - A30
  • [30] CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer
    Molina, Victor
    Visa, Laura
    Conill, Carles
    Navarro, Salvador
    Escudero, Jose M.
    Auge, Jose M.
    Filella, Xavier
    Lopez-Boado, Miguel A.
    Ferrer, Joana
    Fernandez-Cruz, Laureano
    Molina, Rafael
    TUMOR BIOLOGY, 2012, 33 (03) : 799 - 807
12345